AC Immune Reports First Live Images of Alpha-Synuclein in Human Brain with New PET Tracer for Neurodegenerative Disease at AD/PDTM Conference
ACI-12589 distinguished multiple system atrophy (MSA) from other a-synucleinopathies and
healthy volunteers
A-syn PET tracers may be developed to diagnose a-synuclein pathologies, including Parkinson’s
disease, Lewy Body Dementia, MSA and others
AC Immune to host a-syn Key Opinion Leader webinar on March 29th
AC Immune SA, a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced the first non-invasive images of pathological alpha-synuclein (a-syn) in human brain and presented positive clinical proof-of-concept data for an a-syn positron emission tomography (PET) tracer as an imaging agent to identify MSA patients. The clinical trial of AC Immune’s wholly owned experimental a-syn PET tracer was conducted by the team of Oskar Hansson MD, PhD, at Lund University and Skåne University Hospital, with the support of a grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF).